Fairfield, Bush & Co. Invitae Corp Transaction History

Fairfield, Bush & Co.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.2 - $2.73 $1,200 - $2,730	-1,000 Reduced 8.35%	10,980 $14.8 Million
Q4 2022 Feb 14, 2023	SELL	$1.71 - $3.61 $9,576 - $20,216	-5,600 Reduced 31.85%	11,980 $22.3 Million
Q3 2022 Nov 07, 2022	SELL	$1.9 - $8.63 $5,510 - $25,027	-2,900 Reduced 14.16%	17,580 $43,000
Q2 2022 Aug 09, 2022	SELL	$2.13 - $9.01 $213 - $901	-100 Reduced 0.49%	20,480 $50,000
Q4 2021 Feb 09, 2022	SELL	$14.7 - $28.67 $104,737 - $204,273	-7,125 Reduced 25.72%	20,580 $314,000
Q3 2021 Nov 08, 2021	SELL	$24.31 - $33.6 $367,081 - $507,360	-15,100 Closed	0 $0
Q2 2021 Aug 02, 2021	SELL	$26.09 - $40.4 $122,623 - $189,880	-4,700 Reduced 23.74%	15,100 $509,000
Q1 2021 May 14, 2021	BUY	$33.06 - $56.93 $89,923 - $154,849	2,720 Added 15.93%	19,800 $756,000
Q4 2020 Feb 12, 2021	BUY	$39.09 - $57.4 $255,257 - $374,822	6,530 Added 61.9%	17,080 $714,000
Q3 2020 Nov 18, 2020	BUY	$28.43 - $44.67 $299,936 - $471,268	10,550 New	10,550 $457,000

1.92M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.